Zalcitabine: An Update of Its Pharmacodynamic and Pharmacokinetic Properties and Clinical Efficacy in the Management of HIV Infection

Drugs

Volumn 53, Issue 6, 1997, Pages 1054-1080

  Adkins, Julie C ^a   Peters, David H ^a   Faulds, Diana ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Didanosine; Human Immuno Deficiency Virus Type; Triple Combination Therapy; Zalcitabine; Zidovudine

Indexed keywords

DRUG; ZALCITABINE; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; CASTANOSPERMINE 6 BUTYRATE; CD4 ANTIGEN; DELAVIRDINE; EMIVIRINE; FOSCARNET; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERFERON; LAMIVUDINE; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; ZIDOVUDINE;

ADVERSE EVENT; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ARTICLE; CLINICAL EFFECTIVENESS; CYTOTOXICITY; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; DRUG TOLERABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; PEDIATRICS; PERIPHERAL NEUROPATHY; PHARMACOECONOMICS; STOMATITIS; CELL COUNT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE COURSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG COST; DRUG CYTOTOXICITY; DRUG HALF LIFE; ENZYME INHIBITION; HYPERSENSITIVITY; INTRAVENOUS DRUG ADMINISTRATION; LIVER TOXICITY; MAJOR CLINICAL STUDY; META ANALYSIS; MOUTH ULCER; ORAL DRUG ADMINISTRATION; SURVIVAL TIME; VIRUS REPLICATION; VIRUS RESISTANCE;

ADULT; ANTI-HIV AGENTS; CHILD; CLINICAL TRIALS; DRUG INTERACTIONS; DRUG RESISTANCE, MICROBIAL; DRUG THERAPY, COMBINATION; DRUG TOLERANCE; HIV INFECTIONS; HIV-1; HUMANS; ZALCITABINE;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0030918031     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/00003495-199753060-00009     Document Type: Article

References (178)

1. Whittinglon R, Brogden RN. Zalcitabine: a review of its pharmacology and clinical potential in acquired immunodeficiency syndrome (AIDS). Drugs 1992 Oct; 44: 656–83
2. Cooney DA, Dalai M, Mitsuyu H, et al. Initial studies on the cellular pharmacology of 2′,3′-dideoxycytidine, an inhibitor of HTLV-III infectivity. Biochem Pharmacol 1986; 35: 2065–8
3. De Jong MD, Boucher CAB, Galasso GJ, et al. Consensus symposium on combined antiviral therapy. Antiviral Res 1996 Jan; 29: 5–29
4. Mitsuya H, Broder S. Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2′,3′-dideoxynucleosides. Proc Natl Acad Sci USA 1986 Mar; 83: 1911–5
5. Brennan TM, Taylor DL, Bridges CG. The inhibition of human immunodeficiency virus type 1 in vitro by a non-nucleoside reverse transcriptase inhibitor MKC-442, alone and in combination with other anti-HIV compounds. Antiviral Res 1995 Mar; 26: 173–87
6. Bridges EG, Dutschman GE, Gullen EA, et al. Favorable interaction of β-L(−) nucleoside analogues with clinically approved anti-HIV nucleoside analogues for the treatment of human immunodeficiency virus. Biochem Pharmacol 1996 Mar 22; 51: 731–6
7. Chong K-T, Pagano PJ, Hinshaw RR. Bisheteroarylpiperazine reverse transcriptase inhibitor in combination with 3′-azido-3′-deoxythymidine or 2′,3′-dideoxycytidine synergistically inhibits human immunodeficiency virus type 1 replication in vitro. Antimicrob Agents Chemother 1994 Feb; 38: 288–93
8. Connell EV, Hsu M-C, Richman DD. Combinative interactions of a human immunodeficiency virus (HIV) Tat antagonist with HIV reverse transcriptase inhibitors and an HIV protease inhibitor. Antimicrob Agents Chemother 1994 Feb; 38: 348–52
9. Craig JC, Whittaker L, Duncan IB. In vitro anti-HIV and cytotoxicological evaluation of the triple combination: AZT and ddC with HIV proteinase inhibitor saquinavir (Ro 31-8959). Antiviral Chem Chemother 1994 Nov; 5: 380–6
10. Craig JC, Duncan IB, Whittaker L, et al. Antiviral synergy between inhibitors of HIV proteinase and reverse transcriptase. Antiviral Chem Chemother 1993; 4(3): 161–6
11. Degré M, Beck S. Anti-HIV activity of dideoxynucleosides, foscarnet and fusidic acid is potentiated by human leukocyte interferon in blood-derived macrophages. Chemotherapy 1994 May–Jun; 40: 201–8
12. Demine CA, Bechtold CM, Stock D, et al. Evaluation of reverse transcriptase and protease inhibitors in two-drug combinations against human immunodeficiency virus replication. Antimicrob Agents Chemother 1996 Jun; 40: 1346–51
13. Eron Jr JJ, Johnson VA, Merrill DP, et al. Synergistic inhibition of replication of human immunodeficiency virus type 1, including that of a zidovudine-resistant isolate, by zidovudine and 2′,3′-dideoxycytidine in vitro. Antimicrob Agents Chemother 1992 Jul; 36: 1559–62
14. Johnson VA, Merrill DP, Chou T-C, et al. Human immunodeficiency virus type 1 (HIV-1) inhibitory interactions between protease inhibitor Ro 31-8959 and zidovudine, 2′,3′-dideoxy-cytidine, or recombinant interferon-α-A against zidovudine-sensitive or -resistant HIV-1 in vitro. J Infect Dis 1992 Nov; 166: 1143–6
15. Mathez D, Schinazi RF, Liotta DC, et al. Infectious amplification of wild-type human immunodeficiency virus from patients’ lymphocytes and modulation by reverse transcriptase inhibitors in vitro. Antimicrob Agents Chemother 1993 Oct; 37: 2206–11
16. Palmer S, Harmenberg J, Cox S. Synergistic inhibition of human immunodeficiency virus isolates (including 3′-azido-3′-deoxythymidine-resistant isolates) by foscarnet in combination with 2′,3′-dideoxyinosine or 2′,3′-dideoxycytidine. Antimicrob Agents Chemother 1996 May; 40: 1285–8
17. Perno C-F, Cooney DA, Gao W-Y, et al. Effects of bone marrow stimulatory cytokines on human immunodeficiency virus replication and the antiviral activity of dideoxynucleosides in cultures of monocyte/macrophages. Blood 1992 Aug 15; 80: 995–1003
18. Taylor DL, Brennan TM, Bridges CG, et al. Synergistic inhibition of human immunodeficiency virus type 1 in vitro by 6-0-butanoylcastanospermine (MDL 28 574) in combination with inhibitors of the virus-encoded reverse transcriptase and proteinase. Antiviral Chem Chemother 1995 May; 6: 143–52
19. Mazzulli T, Rusconi S, Merrill DP, et al. Alternating versus continuous drug regimens in combination chemotherapy of human immunodeficiency virus type 1 infection in vitro. Antimicrob Agents Chemother 1994 Apr; 38: 656–61
20. Veal GJ, Barry MG, Back DJ. Zalcitabine (ddC) phosphorylation and drug interactions. Antiviral Chem Chemother 1995 Nov; 6: 379–84
21. Veal GJ, Wild MJ, Barry MG, et al. Effects of dideoxyinosine and dideoxycytidine on the intracellular phosphorylation of zidovudine in human mononuclear cells. Br J Clin Pharmacol 1994 Oct; 38: 323–8
22. Veal GJ, Hoggard PG, Barry MG, et al. Interaction between lamivudine (3TC) and other nucleoside analogues for intracellular phosphorylation. AIDS 1996 May; 10: 546–8
23. Baba M, Pauwels R, Balzarini J, et al. Ribavirin antagonizes inhibitory effects of pyrimidine 2′,3′-dideoxynucleosides on replication of human immunodeficiency virus in vitro. Antimicrob Agents Chemother 1987 Oct; 31(10): 1613–7
24. Faraj A, Fowler DA, Bridges EG, et al. Effects of 2′,3′-dideoxynucleosides on proliferation and differentiation of human pluripotent progenitors in liquid culture and their effects on mitochondrial DNA synthesis. Antimicrob Agents Chemother 1994 May; 38: 924–30
25. Johnson M, Caiazzo T, Molina J-M, et al. Inhibition of bone marrow myelopoiesis and erythropoiesis in vitro by anti-retroviral nucleoside derivatives. Br J Haematol 1988 Oct; 70: 137–41
26. Steinberg HN, Zekdis JB. The effect of the antiviral dideoxycytidine (DDC) on the growth of human bone marrow progenitor cells in vitro. Proc Am Soc Clin Oncol 1988 Mar; 7: abstr. 14
27. Nusbaum NJ, Abraham T. Combination antiretroviral chemotherapy: a potential strategy in AIDS-related malignancy. Anticancer Drugs 1996 Jan; 7: 109–13
28. Zhang H, Cooney DA, Sreenath A, et al. Quantitation of mito-chondrial DNA in human lymphoblasts by a competitive polymerase chain reaction method: application to the study of inhibitors of mitochondrial DNA content. Mol Pharmacol 1994 Dec; 46: 1063–9
29. Lewis LD, Hamezeh FM, Lietman PS. Ultrastructural changes associated with reduced mitochondrial DNA and impaired mitochondrial function in the prescence of 2′3′-dideoxycytidine. Antimicrob Agents Chemother 1992 Sep; 36: 2061–5
30. Medina DJ, Tsai C-H, Hsiung GD, et al. Comparison of mitochondrial morphology, mitochondrial DNA content, and cell viability in cultured cells treated with three anti-human immunodeficiency virus dideoxynucleosides. Antimicrob Agents Chemother 1994 Aug; 38: 1824–8
31. Magnani M, Casabianca A, Rossi L, et al. Inhibition of HIV-1 and LP-BM5 replication in macrophages by dideoxycytidine and dideoxycytidine 5′-triphosphate. Antiviral Chem Chemother 1995 Sep; 6: 312–9
32. Keilbaugh SA, Hobbs GA, Simpson MV. Anti-human immunodeficiency virus type 1 therapy and peripheral neuropathy: prevention of 2′,3′-dideoxycytidine toxicity in PC12 cells, a neuronal model, by uridine and pyruvate. Mol Pharmacol 1993 Oct; 44: 702–6
33. Lewis W, Dalakas MC. Mitochondrial toxicity of antiviral drugs. Nat Med 1995 May; 1: 417–22
34. Sommadossi J-P. Nucleoside analogs: similarities and differences. Clin Infect Dis 1993 Feb; 16 Suppl. 1: S7–15
35. Chen C-H, Cheng Y-C. Delayed cytotoxicity and selective loss of mitochondrial DNA in cells treated with the anti-human immunodeficiency virus compound 2′,3′-dideoxycytidine. J Biol Chem 1989 Jul 15; 264: 11934–7
36. Anderson TD, Davidovich A, Feldman D, et al. Mitochondrial schwannopathy and peripheral myelinopathy in a rabbit model of dideoxycytidine neurotoxicity. Lab Invest 1994 May; 70: 724–39
37. Toltzis P, Mourton T, Magnuson T. Comparative embryonic cytotoxicity of antiretroviral nucleosides. J Infect Dis 1994 May; 169: 1100–2
38. Luster MI, Rosenthal GJ, Cao W, et al. Experimental studies of the hematologic and immune system toxicity of nucleoside derivatives used against HIV infection. Int J Immunopharmacol 1991; 13 Suppl 1: 99–107
39. Brandi G, Casabianca A, Schiavano GF, et al. Efficacy and toxicity of long-term administration of 2′,3′-dideoxycytidine in the LP-BM5 murine-induced immunodeficiency model. Antiviral Chem Chemother 1995 May; 6: 153–61
40. Coffin JM. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 1995; 267: 483–9
41. Moyle GJ. Use of viral resistance patterns to antiretroviral drugs in optimising selection of drug combinations and sequences. Drugs 1996 Aug; 52: 168–85
42. Arts EJ, Wainberg MA. Mechanisms of nucleoside analog antiviral activity and resistance during human immunodeficiency virus reverse transcription. Antimicrob Agents Chemother 1996; 40: 527–40
43. Craig C, Moyle G. The development of resistance of HIV-1 to zalcitabine. AIDS 1997; 11: 271–9
44. Smith M, Salomon W, Wainberg MA. Development and significance of nucleoside drug resistance in infection caused by the human immunodeficiency virus type 1. Clin Invest Med 1994 Jun; 17: 226–43
45. Larder BA. Viral resistance and the selection of antiretroviral combinations. J Acquir Immune Defic Syndrom Hum Retrovirol 1995; 10 Suppl. 1: 28–33
46. Tantillo C, Ding JP, Jacobo-Molina A, et al. Locations of antiAIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase: implications for mechanisms of drug inhibition and resistance. J Mol Biol 1994 Oct 28; 243: 369–87
47. Shirasaka T, Yarchoan R, O’Brien MC, et al. Changes in drug sensitivity of human immunodeficiency virus type 1 during therapy with azidothymidine, dideoxycytidine, and dideoxy-inosine: an in vitro comparative study. Proc Natl Acad Sci USA 1993 Jan 15; 90: 562–6
48. Sylvester S, Caliendo A, Sepkowitz K, et al. HIV-1 resistance mutations and plasma RNA levels during ZDV + ddC combination therapy [abstract]. 3rd Conference on Retroviruses and Opportunistic Infections 1996 Jan 28: 107
49. Harrigan PR, Kemp SD, Kinghorn I, et al. A placebo controlled trial of AZT alone or in combination with DDI or DDC: viral load and drug resistance [abstract]. AIDS 1994 Nov; 8 Suppl. 4: S20
50. Richman DD, Meng T-C, Spector SA, et al. Resistance to AZT and ddC during long-term combination therapy in patients with advanced infection with human immunodeficiency virus. J Acquir Immune Defic Syndr 1994 Feb; 7: 135–8
51. Fitzgibbon JE, Howell RM, Haberzettl CA, et al. Human immunodeficiency virus type 1 pol gene mutations which cause decreased susceptibility to 2′,3′-dideoxycytidine. Antimicrob Agents Chemother 1992 Jan; 36: 153–7
52. Zhang D, Caliendo AM, Eron JJ, et al. Resistance to 2′,3′-dideoxycytidine conferred by a mutation in codon 65 of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 1994 Feb; 38: 282–7
53. Gu Z, Gao Q, Fang H, et al. Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2′,3′-dideoxy-cytidine and 2′,3′-dideoxy-3′-thiacytidine. Antimicrob Agents Chemother 1994 Feb; 38: 275–81
54. Gu Z, Arts EJ, Parniak MA, et al. Mutated K65R recombinant reverse transcriptase of human immunodeficiency virus type 1 shows diminished chain termination in the presence of 2′,3′-dideoxycytidine 5′-triphosphate and other drugs. Proc Natl Acad Sci USA 1995 Mar 28; 92: 2760–4
55. Gu Z, Salomon H, Cherrington JM, et al. K65R mutation of human immunodeficiency virus type 1 reverse transcriptase encodes cross-resistance to 9-(2-phosphonylmethoxy-ethyl) adenine. Antimicrob Agents Chemother 1995 Aug; 39: 1888–91
56. Gu ZX, Gao Q, Li XG, et al. Novel mutation in the human immunodeficiency virus type-1 reverse transcriptase gene that encodes cross-resistance to 2′,3′-dideoxyinosine and 2′,3′-dideoxycytidine. J Virol 1992 Dec; 66: 7128–35
57. Gao Q, Gu Z, Parniak MA, et al. The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2′,3′-dideoxyinosine and 2′,3′-dideoxycytidine confers high-level resistance to the (−) enantiomer of 2′,3′-dideoxy-3′-thiacytidine. Antimicrob Agents Chemother 1993 Jun; 37: 1390–2
58. Fitzgibbon JE, Farnham AE, Sperber SJ, et al. Human immunodeficiency virus type-1 pol gene mutations in an AIDS patient treated with multiple antiretroviral drugs. J Virol 1993 Dec; 67: 7271–5
59. Loveday C. HIV-1 genotypic and phenotypic resistance in Delta patients [abstract no. Th.B4354]. 11th International Conference on AIDS, Vancouver July 1996
60. Larder BA, Kohli A, Bloor S, et al. Human immunodeficiency virus type I drug susceptibility during zidovudine (AZT) monotherapy compared with AZT plus 2′,3′-dideoxyinosine or AZT plus 2′,3′-dideoxycytidine combination therapy. J Virol 1996; 70: 5922–9
61. Lacey SF, Larder BA. Novel mutation (V75T) in human immunodeficiency virus type 1 reverse transcriptase confers resistance to 2′,3′-didehydro-2′,3′-dideoxythymidine in cell culture. Antimicrob Agents Chemother 1994 Jun; 38: 1428–32
62. Shirasaka T, Kavlick MF, Ueno T, et al. Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proc Natl Acad Sci USA 1995 Mar 14; 92: 2398–402
63. Schmit JC, Cogniaux J, Hermans P, et al. Multiple drug resistance to nucleotide analogues and nonnucleoside reverse transcriptase inhibitors in an efficiently replicating human immunodeficiency virus type 1 patient strain. J Infect Dis 1996; 174: 962–8
64. Nájera I, Richman DD, Olivares I, et al. Natural occurrence of drug resistance mutations in the reverse transcriptase of human immunodeficiency virus type 1 isolates. AIDS Res Hum Retroviruses 1994 Nov; 10: 1479–88
65. Cinatl Jr J, Cinatl J, Weber B, et al. Decreased anti-human immunodeficiency virus type-1 activities of 2′,3′-dideoxy-nucleoside analogs in MOLT-4 cell sublines resistant to 2′,3′-dideoxynucleoside analogs. Acta Virol 1993 Oct; 37: 360–8
66. Cinatl Jr J, Cinatl J, Rabenau H, et al. Failure of antiretroviral therapy: role of viral and cellular factors. Intervirology 1994 Nov–Dec; 37: 307–14
67. Perno CF, Yarchoan R, Bulzarini J, et al. Different pattern of activity of inhibitors of the human immunodeficiency virus in lymphocytes and monocyte/macrophages. Antiviral Res 1992 Apr; 17: 289–304
68. Perno CF, Yarchoan R, Cooney DA, et al. Inhibition of human immunodeficiency virus (HIV-1/HTLV-IIIBa-L) replication in fresh and cultured human peripheral blood monocytes/ macrophages by azidothymidine and related 2′,3′-dideoxy-nucleosides. J Exp Med 1988 Sep 1; 168: 1111–25
69. Perno CF, Cooney D, Yarchona R, et al. Inhibition of human immunodeficiency virus (HIV) infections of fresh peripheral blood monocyte/macrophages (M/M) by dideoxynucleosides and phosphonoformate. Antiviral Res 1988; 9: 157
70. Hengstschläger M, Denk C, Wawra E. Cell cycle regulation of deoxycytidine kinase. Evidence for post-transcriptional control. FEBS Lett 1993; 321: 237–40 7.
71. Arnér ESJ, Eriksson S. Mammalian deoxyribonucleoside kinases. Pharmacol Ther 1995; 67: 155–86
72. Gao W-Y, Agbaria R, Driscoll JS, et al. Divergent anti-human immunodeficiency virus activity and anabolic phosphorylation of 2′,3′-dideoxynucleoside analogs in resting and activated human cells. J Biol Chem 1994 Apr 29; 269: 12633–8
73. Gao W-Y, Shirasaka T, Johns DG, et al. Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells. J Clin Invest 1993 May; 91: 2326–33
74. Watson AJ, Wilburn LM. Inhibition of HIV infection of resting peripheral blood lymphocytes by nucleosides. AIDS Res Hum Retroviruses 1992 Jul; 8: 1221–7
75. Perno CF, Aquaro S, Rosenwirth B, et al. In vitro activity of inhibitors of late stages of the replication of HIV in chronically infected macrophages. J Leukoc Biol 1994 Sep; 56: 381–6
76. Magnani M, Gazzanelli G, Brandi G, et al. 2′,3′-Dideoxycytidine induced drug resistance in human cells. Life Sci 1995 Jul 21; 57: 881–7
77. Magnani M, Brandi G, Casablanca A, et al. 2′,3′-Dideoxycytidine metabolism in a new drug-resistant cell line. Biochem J 1995 Nov 15; 312 (Pt 1): 115–23
78. Gustavson LE, Fukuda EK, Rubio FA, et al. A pilot study of the bioavailability and pharmacokinetics of 2′,3′-dideoxycytidine in patients with AIDS or AIDS-related complex. J Acquir Immune Defic Syndr 1990; 3: 28–31
79. Klecker Jr RW, Collins JM, Yarchoan RC, et al. Pharmacokinetics of 2′,3′-dideoxycytidine in patients with AIDS and related disorders. J Clin Pharmacol 1988 Sep; 28: 837–42
80. Gould Chadwick E, Nazareno LA, Nieuwenhuis TJ, et al. Phase I evaluation of zalcitabine administered to human immunodeficiency virus-infected children. J Infect Dis 1995 Dec; 172: 1475–9
81. Pizzo PA, Butler K, Balis F, et al. Dideoxycytidine alone and in an alternating schedule with zidovudine in children with symptomatic human immunodeficiency virus infection. J Pediatr 1990 Nov; 117: 799–808
82. Dudley MN. Clinical pharmacokinetics of nucleoside antiretroviral agents. J Infect Dis 1995 Mar; 171 Suppl. 2: S99–112
83. Morse GD, Shelton MJ, O’Donnell AM. Comparative pharmacokinetics of antiviral nucleoside analogues. Clin Pharmacokinel 1993 Feb; 24: 101–23
84. Devineni D, Gallo JM. Zalcilabine: clinical pharmacokinetics and efficacy. Clin Pharmacokinet 1995 May; 28: 351–60
85. Shelton MJ, O’Donnell AM, Morse GD. Zalcilabine. Ann Pharmacother 1993 Apr; 27: 480–9
86. Kaslrissios H, Nakano M, Burton P, et al. Improved combined solid-phase extraction-RIA method for quantifying zalcitabine in plasma. Clin Chem 1996 Mar; 42: 465–6
87. Burger DM, Rosing H, ten Napel CHH, el al. Application of a radioimmunoassay for determination of levels of zalcitabine (ddC) in human plasma, urine, and cerebrospinal fluid. Anli-microb Agents Chemother 1994 Dec; 38: 2763–7
88. Roberts WL, Buckley TJ, Rainey PM, et al. Solid-phase extraction combined with radioimmunoassay for measurement of zalcitabine (2′,3′-dideoxycytidine) in plasma and serum. Clin Chem 1994 Feb; 40: 211–5
89. Nazareno LA, Holazo AA, Limjuco R, et al. The effect of food on pharmacokinetics of zalcitabine in HIV-positive patients. Pharm Res 1995 Oct; 12: 1462–5
90. Yarchoan R, Perno CF, Thomas RV, el al. Phase I studies of 2′,3′-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT). Lancet 1988 Jan 16; I: 76–81
91. Bazunga M, Tran HT, Kertland H, et al. The effects of renal impairment on the pharmacokinetics of Zalcitabine (ddC) [abstract]. J Clin Pharmacol 1996 Sep; 36: 851
92. Roche. HIVID tablets; product descripion. June 1996
93. Aiuti F, Boucher C, Dianzani F, et al. Consensus conference on laboratory markers in HIV infection. J Biol Regul Homeost Agents l995 Jul–Sep; 9: 119–20
94. Goldman AI, Carlin BP, Crane LR, et al. Response of CD4 lymphocytes and clinical consequences of treatment using ddI or ddC in patients with advanced HIV infection. J Acquir Immune Defic Syndrom Hum Retrovirol 1996 Feb 1; 11: 161–9
95. + lymphocytes are an incomplete surrogate marker for clinical progression in persons with asymptomatic HIV infection taking zidovudine. Ann Intern Med 1993; 118: 674–80
96. Williams IG, De Cock KM. The XI International Conference on AIDS Vancouver 7–12 July 1996. Areview of Clinical Science Track B. Genitourin Med 1996; 72: 365–9
97. Harrigan R. Measuring viral load in the clinical setting. J Acquir Immune Defic Syndrom Hum Retrovirol 1995; 10 Suppl. 1: S34–40
98. Katzenstein DA, Hammer SM, Hughes MD, et al. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infecled adults with 200 to 500 CD4 cells per cubic millimeter. N Engl J Med 1996 Oct 10; 335: 1091–8
99. Deyton L. Importance of surrogate markers in evaluation of antiviral therapy in HIV infection. JAMA 1996; 276: 159–60
100. Levy JA. Surrogate markers in AIDS research. Is there truth in numbers? JAMA 1996; 276: 161–2
101. Forsyth BWC. Primary care of children with HIV infection. Curr Opin Pediatr 1995 Oct; 7: 502–12
102. Pizzo PA, Wilfert C. Antiretroviral therapy for infection due to human immunodeficiency virus in children. Clin Infect Dis 1994 Jul; 19: 177–96
103. Mofenson L, Balsley J, Simonds RJ, et al. Recommendations of the U.S. Public Health Service Task Force on the use of zidovudine to reduce perinatal transmission of human immunodeficiency virus. MMWR 1994 Aug 5; 43: 1–20
104. Mildvan D, Bergé P. Prophylactic zalcilabine and interferon-α for a large-bore needlestick exposure to human immunodeficiency virus. J Acquir Immune Defic Syndr 1994 Apr; 7: 416–7
105. Update: Provisional Public Health Service recommendations for chemoprophyIaxis after occupational exposure to HIV. MMWR 1996 Jun 7; 45: 468–72
106. Portegies P. HIV-1, the brain, and combination therapy. Lancet 1995 Nov 11; 346: 1244–5
107. Everall IP. Neuropsychiatric aspects of HIV infection. J Neurol Neurosurg Psychiatry 1995 Apr; 58: 399–402
108. Goebel FD. Combination therapy from a clinician’s perspective. J Acquir Immune Defic Syndrom Hum Retrovirol 1995; 10 Suppl. 1: S62–68
109. McIntyre K, Torres R, Luck D, et al. Pilot study of zidovudine (AZT) and zalcitabine (ddC) combination in HIV-associated dementia [abstract]. 10th International Conference on AIDS 1994; 1: 201
110. Follansbee S, Drew L, Olson R, et al. The efficacy of zalcitabine (ddC, HIVID) versus zidovudine (ZDV) as monotherapy in ZDV naive patients with advanced HIV disease: a randomized, double-blind, comparative trial (ACTG 114: N3300) [abstract]. 9th Int Conf Aids 1993; 1: 487
111. Bozzette SA, Kanouse DE, Berry S, et al. Health status and function with zidovudine or zalcitabine as initial therapy for AIDS: a randomized controlled trial. JAMA 1995 Jan 25; 273: 295–301
112. Torres RA, Barr MR, Mclntyre KI, et al. A comparison of zidovudine, didanosine, zalcitabine and no antiretroviral therapy in patients with advanced HIV disease. Int J STD AIDS 1995 Jan–Feb; 6: 19–26
113. Abrams DI, Goldman AI, Launer C, et al. A comparative trial of didanosine or zalcitabine after treatment with zidovudine in patients with human immunodeficiency virus infection. N Engl J Med 1994 Mar 10; 330: 657–62
114. Fischl MA, Olson RM, Follansbee SE, et al. Zalcitabine compared with zidovudine in patients with advanced HI V-1 infection who received previous zidovudine therapy. Ann Intern Med 1993 May 15; 118: 762–9
115. Fischl MA, Stanley K, Collier AC. Combination and monotherapy with zidovudine and zalcitabine in patients with advanced HIV disease. Ann Intern Med 1995 Jan 1; 122: 24–32
116. Hammer SM, Katzenstein DA, Hughes MD, et al. A trial comparing nucleoside monotherapy with combination therapy in HI V-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N Engl J Med 1996 Oct 10; 335: 1081–90
117. Collier AC, Coombs RW, Schoenfeld DA, et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. N Engl J Med 1996 Apr 18; 334: 1011–7
118. Schooley RT, Ramirez-Ronda C, Lange JMA, et al. Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy. J Infect Dis 1996 Jun; 173: 1354–66
119. Katlama C. Clinical and survival benefit of 3TC™ in combination with zidovudine-containing regimens in HIV-1 infection: interim results of the CAESAR study [abstract no. SS2.1]. AIDS 1996; 10 Suppl.: S9
120. Saravolatz LD, Winslow DL, Collins G, et al. Zidovudine alone or in combination with didanosine or zalcitabine in HIV-inlected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter. N Engl J Med 1996 Oct 10; 335: 1099–106
121. Delta Coordinating Committee. Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet 1996 Aug 3; 348: 283–91
122. 3: a double-blind placebo controlled trial (Roche study M50003) [abslract no. P49]. AIDS 1996; 10 Suppl. 2: S31
123. Bartlett JA, Benoit SL, Johnson VA. Lamivudine plus zidovudine compared with zalcilabine plus zidovudine in patients with HIV infection: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1996 Aug 1; 125: 161–72
124. Hoffman-La Roche. HIVID®: combination therapy in HIV disease. Clinical expert report
125. Meng T-C, Fischl MA, Boota AM, et al. Combination therapy with zidovudine and dideoxycytidine in patients with advanced human immunodeficiency virus infection. Ann Med 1992; 116(1): 13–20
126. Henry K, Tierney C, Kahn J, et al. A randomized, double-blind, placebo-controlled study comparing combination nucleoside and triple therapy for the treatment of advanced HIV disease (CD4 < = 50/mm3) [abstract]. 4th Conference on Retroviruses and Opportunistic Infections; 1997 Jan 22–26; Washington, DC
127. Thompson M, Creagh T, Harmon M, et al. Impact on survival of combination or sequential antiretroviral therapy compared with AZT monotherapy [abstract]. 3rd Conference on Retroviruses and Opportunistic Infections 1996 Jan 28: 106
128. Graham NMH, Hoover DR, Park LP, et al. Survival in HIV-infected patients who have received zidovudine: comparison of combination therapy with sequential monotherapy and continued zidovudine monotherapy. Ann Intern Med 1996 Jun 15; 124: 10310–1038
129. Lange JMA. Triple combinations: present and future. J Acquir Immune Defic Syndrom Hum Retrovirol 1995; 10 Suppl. 1: 77–82
130. Testa MA, Lenderking WR, Fischer L, et al. Effects of combination therapy with saquinavir, zidovudine and zalcitabine on quality of life [abstract]. 11th International Conference on AIDS 1996 Jul 7; 1: 239
131. Ruiz L, Romeu J, Martinez-Picado J, et al. Efficacy of triple combination therapy with zidovudine (ZDV) plus zalcitabine (ddC) plus lamivudine (3TC) versus double (ZDV + 3TC) combination therapy in patients previously treated with ZDV + ddC. AIDS 1996; 10: F61–6
132. Mathez D, Bagnarelli P, De Truehis P, et al. A triple combination of ritonavir+AZT+DDC as a first line treatment of patients with AIDS: update [abstract]. 11th International Conference on AIDS 1996 Jul 7; 1: 19
133. Conde-Mercado JM, Feregrino GM, Eid Lidt G, et al. Antiviral combined and thymostimulin in patients with HIV stages III and IV. Effects on the CD4 cells counts [abstract]. 10th International Conference on AIDS 1994; 1: 211
134. Lavelle J, Haas D, HIV/Wellferon® Clinical Trial Team. Long-term safety and efficacy of initial triple combination therapy with ZDV, ddC and interferon alpha-n1 vs ZDV and ddC in patients with CD4+ cell counts 300–500 cells/mm3. 3rd Conference on Retroviruses and Opportunistic Infections 1996 Jan 28: 107
135. Freimuth W, Wang Y, Docsa S, et al. Surrogate marker responses from an open-label, extended use delavirdine mesylate (DLV) treatment in triple combination (ZDV+DLV +DDI or ZDV+DLV+DDC) for HIV-1+ patients [abstiact]. 11th International Conference on AIDS 1996 Jul 7; 1: 78
136. Scheibel SF, Saget B, Elbeik T, et al. Extreme suppression of HIV-1 plasma RNA using a combination of zidovudine, didanosine, zalcitabine, epivir, saquinavir, and interferon-α in patients with HIV-I infection [abstract]. 11th International Conference on AIDS 1996 Jul 7; 2: 78
137. Spector SA, Blanchard S, Connor EM, et al. Results of a clinical trial comparing two doses of 2′3′-dideoxycytidine (ddC) in the treatment of children with symptomatic human immunodeficiency virus (HIV) infection who were intolerant or had failed zidovudine (ZDV) therapy (ACTG 138) [abstract]. Pediatr Res 1994 Apr; 35 (Pt 2): 197A
138. Dankner WM, Rice M, Nyhan WL, et al. Effect of salvage dideoxycytidine on growth, nutritional parameters and metabolic rates of children with advanced HIV disease [abstract]. 2nd National Conference on Human Retroviruses 1995 Jan 29: 104
139. Husson R, Shirasaka T, Butler K, et al. High level resistance to AZT, but not to ddC or ddI in HIV from children receiving long-term antiretroviral therapy [abslract no. 571]. 32nd Inl Conf Antimicro Ag Chemother 1992: 206
140. Simpson K, Hatziandreu EJ, Andersson F, et al. Cost effectiveness of antiviral treatment with zalcitabine plus zidovudine for AIDS patients with CD4+ counts less than 33/μl in 5 European countries. PharmacoEconomics 1994 Dec; 6: 553–62
141. Merigan TC. Treatment of AIDS with combinations of anti-retroviralagents. Am J Med 1991; 90 Suppl. 4A: 8S–17S
142. Moyle G, Goll A, Snape S, et al. Safety and tolerability of zalcitabine (ddC) in patients with AIDS or advanced AIDS-related complex in the European Expanded Access Programme. Int J Antimicrob Agents 1996; 7(1): 41–8
143. Moore RD, Fortgang I, Keruly J, et al. Adverse events from drug therapy for human immunodeficiency virus disease. Am J Med 1996 Jul; 101: 34–40
144. Simpson DM, Tagliati M. Nucleoside analogue-associated peripheral neuropathy in human immunodeficiency virus infection. J Acquir Immune Defic Syndrom Hum Retrovirol 1995 Jun 1; 9: 153–61
145. Blum AS, Dal PGJ, Feinberg J, et al. Low-dose zalcitabine-related toxic neuropathy: frequency, natural history, and risk factors. Neurology 1996 Apr; 46: 999–1003
146. Fichtenbaum CJ, Clifford DB, Powderly WG. Risk factors for dideoxynucleoside-induced toxic neuropathy in patients with the human immunodeficiency virus infection. J Acquir Immune Defic Syndrom Hum Retrovirol 1995 Oct 1; 10: 169–74
147. Berger AR, Arezzo JC, Schaumburg HH, et al. 2′,3′-dideoxy-cytidine (ddC) toxic neuropathy: a study of 52 patients. Neurology 1993 Feb; 43: 358–62
148. Dubinsky RM, Yarchoan R, Dalakas M, et al. Reversible axonal neuropathy from the treatment of AIDS and related disorders with 2′,3′-dideoxycytidine (ddC). Muscle Nerve 1989; 12: 856–60
149. Lipsky JJ. Zalcitabine and didanosine. Lancet 1993 Jan 2; 341: 30–2
150. Powderly WG, Klebert MK, Clifford DB. Ototoxicity associated with dideoxycytidine [letter]. Lancet 1990 May 5; 335: 1106
151. Martinez OP, French MAH. Acoustic neuropathy associated with zalcitabine-induced peripheral neuropathy. AIDS 1993 Jun; 7: 901–2
152. Faller JP, Ziegler F, Balblanc JC, et al. Acute paralysis of the serratus muscle in an HIV positive patient treated by DDC [abstract]. 10th International Conference on AIDS 1994; 1: 191
153. Jay C, Ropka M, Dalakas MC. The drugs 2′,3′-dideoxyinosine (ddI) and 2′,3′-dideoxycytidine (ddC) are safe alternatives in people with AIDS with zidovudine-induced myopathy. J Acquir Immune Defic Syndr 1994 Jun; 7: 630–1
154. Greenspan D, Hilton JF, Canchola AJ, et al. Association between oral ulcers and zalcitabine [abstract]. 10th International Conference on AIDS 1994; 1: 62
155. Ramirez-Ronda CH, Santana J, Rivera-Vazquez C, et al. Oral ulcers in HIV infected persons taking zalcitabine plus zidovudine: initial results [abstract]. 2nd National Conference on Human Retroviruses 1995 Jan 29: 153
156. Indorf AS, Pegram PS. Esophageal ulceration related to zalcitabine (ddC). Ann Intern Med 1992 Jul 15; 117: 133–4
157. Merigan TC, Skowron G, Bozzette SA, et al. Circulating p24 antigen levels and responses to dideoxycytidine in human immunodeficiency virus (HIV) infections. A phase I and II study. Ann Intern Med 1989 Feb 1; 110: 189–94
158. McNeely MC, Yarchoan R, Broder S, et al. Dermatologic complications associated with administration of 2′,3′-dideoxy-cytidine in patients with human immunodeficiency virus infection. J Am Acad Dermatol 1989 Dec; 21: 1213–7
159. Wardropper AG, Ong ELC. Erythema multiforme secondary to dideoxycytidine (DDC). Int J STD AIDS 1995 Nov–Dec; 6: 450
160. Tancrede-Bohlin E, Grange F, Bournerias I. Hypersensitivity syndrome associated with zalcitabine therapy. Lancet 1996 Apr 6; 347: 971
161. Henry K, Acosta EP. Hepatotoxicity and rash associated with zidovudine and zalcitabine chemoprophylaxis. Ann Intern Med 1996 May 1; 124: 855
162. Brivet FG, Naveau SH, Lemaigre GF, et al. Pancreatic lesions in HIV-infected patients. Baillieres Clin Endocrinol Metab 1994 Oct; 8: 859–77
163. Aponte-Cipriani SL, Teplitz C, Yancovitz S. Pancreatitis possibly related to 2′-3′-dideoxycytidine. Ann Intern Med 1993 Sep 15; 119: 539–40
164. Moyle GJ. Occurrence of lymphomas during ddC or ddC/ zidovudine combination therapy in persons infected with HIV type I [letter]. J Acquir Immune Defic Syndrom Hum Retrovirol 1996; 13(5): 464–5
165. 3. Antiviral Ther 1996 Aug; 1(3): 180–8
166. Acosta EP, Fletcher CV. Antiretroviral drug interactions. Int J Antimicrob Agents 1995 Apr; 5: 73–83
167. Taburet A-M, Singlas E. Drug interactions with antiviral drugs. Clin Pharmacokinet 1996 May; 30: 385–401
168. Heylen R, Miller R. Interactions with antiretroviral drugs. Pharm J 1993 Feb 13; 250: 214–6
169. (Rm) on the pharmacokinetics of zalcitabine in HIV-positive patients [abstract]. Pharm Res 1994 Oct; 11 Suppl.: S-415
170. Massarella JW, Nazareno LA, Passe S, et al. The effect of probenecid on the pharmacokinetics of zalcitabine in HIV-positive patients. Pharm Res 1996 Mar; 13: 449–52
171. Lee BL, Tauber MG, Chambers HF, et al. The effect of trimethoprim on the pharmacokinetics of zalcitabine in HIV-infected patients [abstract]. 35th Int Conf Antimicro Ag Chemother 1995 Sep 17: 6
172. LeLacheur SF, Simon GL. Exacerbation of dideoxycytidine-induced neuropathy with dideoxyinosine. J Acquir Immune Defic Syndr 1991; 4: 538–9
173. Herskowitz A, Willoughby SB, Baughman KL, et al. Cardiomyopathy associated with antiretroviral therapy in patients with HIV infection: a report of six cases. Ann Intern Med 1992 Feb 15; 116: 311–3
174. MacGregor TR, Lamson MJ, Cort S, et al. Steady state pharmacokinetics of nevirapine, didanosine, zalcitabine, and zidovudine combination therapy in HIV-1 positive patients [abstract]. Pharm Res 1995 Sep; 12 Suppl.: S101
175. Lee BL, Tauber MG, Chambers HF, et al. Zalcitabine and dapsone pharmacokinetic interaction in HIV-infected patients [abstract]. Clin Pharmacol Ther 1995 Feb; 57: 186
176. Lee BL, Täuber MG, Chambers HF, et al. The effect of zalcitabine on the pharmacokinetics of isoniazid in HIV-infected patients [abstract no. A4]. 34th Int Conf Antimicro Ag Chemother 1994: 3
177. Hoffman La Roche. Zalcitabine prescribing information. Basel, Switzerland, 1997
178. Carpenter CCJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1996: recommendations of an international panel. JAMA 1996 Jul 10; 276: 146–54